Earl Clarke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Earl Clarke has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Carl Hobbs
The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, UK
5 shared publications- Jonathan P. T. Corcoran
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre, King's College London, Guy's Campus, London, United Kingdom
5 shared publications Julian Jack
The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, UK
4 shared publicationsMaria B. Goncalves
Kings Coll London, Wolfson Ctr Age Related Dis, Neurosci Drug Discovery Unit, Guys Campus, London SE1 1UL, England
4 shared publicationsJohn Grist
The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, UK
3 shared publications- Alan D. Borthwick
Pharmaron UK Ltd.
2 shared publications
Latest Publications
- Open Access
- 6 September 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-10
Drug repurposing for Alzheimer’s disease based on transcriptional profiling of human iPSC-derived cortical neurons
Alzheimer’s disease is a complex disorder encompassing multiple pathological features with associated genetic and molecular culprits. However, target-based therapeutic strategies have so far proved ineffective. The aim of this study is to develop a methodology harnessing the transcriptional changes associated with Alzheimer’s disease to develop a high content quantitative disease phenotype that can be used to repurpose existing drugs. Firstly, the Alzheimer’s disease gene expression landscape covering severe disease stage, early pathology progression, cognitive decline and animal models of the disease has been defined and used to select a set of 153 drugs tending to oppose disease-associated changes in the context of immortalised human cancer cell lines. The selected compounds have then been assayed in the more biologically relevant setting of iPSC-derived cortical neuron cultures. It is shown that 51 of the drugs drive expression changes consistently opposite to those seen in Alzheimer’s disease. It is hoped that the iPSC profiles will serve as a useful resource for drug repositioning within the context of neurodegenerative disease and potentially aid in generating novel multi-targeted therapeutic strategies.
- 6 September 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-10
Open AccessDrug repurposing for Alzheimer’s disease based on transcriptional profiling of human iPSC-derived cortical neurons
Alzheimer’s disease is a complex disorder encompassing multiple pathological features with associated genetic and molecular culprits. However, target-based therapeutic strategies have so far proved ineffective. The aim of this study is to develop a methodology harnessing the transcriptional changes associated with Alzheimer’s disease to develop a high content quantitative disease phenotype that can be used to repurpose existing drugs. Firstly, the Alzheimer’s disease gene expression landscape covering severe disease stage, early pathology progression, cognitive decline and animal models of the disease has been defined and used to select a set of 153 drugs tending to oppose disease-associated changes in the context of immortalised human cancer cell lines. The selected compounds have then been assayed in the more biologically relevant setting of iPSC-derived cortical neuron cultures. It is shown that 51 of the drugs drive expression changes consistently opposite to those seen in Alzheimer’s disease. It is hoped that the iPSC profiles will serve as a useful resource for drug repositioning within the context of neurodegenerative disease and potentially aid in generating novel multi-targeted therapeutic strategies.
- Open Access
- 1 April 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (8) , 995-1000
Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury
- 1 April 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (8) , 995-1000
Open AccessDiscovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury
- Open Access
- 13 February 2019
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 39 (16) , 3013-3027
Regulation of Myelination by Exosome Associated Retinoic Acid Release from NG2-Positive Cells
In the CNS, oligodendrocytes are responsible for myelin formation and maintenance. Following spinal cord injury, oligodendrocyte loss and an inhibitory milieu compromise remyelination and recovery. Here, we explored the role of retinoic acid receptor-beta (RARβ) signaling in remyelination. Using a male Sprague Dawley rat model of PNS-CNS injury, we show that oral treatment with a novel drug like RARβ agonist, C286, induces neuronal expression of the proteoglycan decorin and promotes myelination and differentiation of oligodendrocyte precursor cells (NG2+cells) in a decorin-mediated neuron–glia cross talk. Decorin promoted the activation of RARα in NG2+cells by increasing the availability of the endogenous ligand RA. NG2+cells synthesize RA, which is released in association with exosomes. We found that decorin prevents this secretion through regulation of the EGFR–calcium pathway. Using functional and pharmacological studies, we further show that RARα signaling is both required and sufficient for oligodendrocyte differentiation. These findings illustrate that RARβ and RARα are important regulators of oligodendrocyte differentiation, providing new targets for myelination.SIGNIFICANCE STATEMENTThis study identifies novel therapeutic targets for remyelination after PNS-CNS injury. Pharmacological and knock-down experiments show that the retinoic acid (RA) signaling promotes differentiation of oligodendrocyte precursor cells (OPCs) and remyelination in a cross talk between neuronal RA receptor-beta (RARβ) and RARα in NG2+cells. We show that stimulation of RARα is required for the differentiation of OPCs and we describe for the first time how oral treatment with a RARβ agonist (C286, currently being tested in a Phase 1 trial,ISRCTN12424734) leads to the endogenous synthesis of RA through retinaldehyde dehydrogenase 2 (Raldh2) in NG2 cells and controls exosome-associated-RA intracellular levels through a decorin–Ca2+pathway. Although RARβ has been implicated in distinct aspects of CNS regeneration, this study identifies a novel function for both RARβ and RARα in remyelination.
- 13 February 2019
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 39 (16) , 3013-3027
Open AccessRegulation of Myelination by Exosome Associated Retinoic Acid Release from NG2-Positive Cells
In the CNS, oligodendrocytes are responsible for myelin formation and maintenance. Following spinal cord injury, oligodendrocyte loss and an inhibitory milieu compromise remyelination and recovery. Here, we explored the role of retinoic acid receptor-beta (RARβ) signaling in remyelination. Using a male Sprague Dawley rat model of PNS-CNS injury, we show that oral treatment with a novel drug like RARβ agonist, C286, induces neuronal expression of the proteoglycan decorin and promotes myelination and differentiation of oligodendrocyte precursor cells (NG2+cells) in a decorin-mediated neuron–glia cross talk. Decorin promoted the activation of RARα in NG2+cells by increasing the availability of the endogenous ligand RA. NG2+cells synthesize RA, which is released in association with exosomes. We found that decorin prevents this secretion through regulation of the EGFR–calcium pathway. Using functional and pharmacological studies, we further show that RARα signaling is both required and sufficient for oligodendrocyte differentiation. These findings illustrate that RARβ and RARα are important regulators of oligodendrocyte differentiation, providing new targets for myelination.SIGNIFICANCE STATEMENTThis study identifies novel therapeutic targets for remyelination after PNS-CNS injury. Pharmacological and knock-down experiments show that the retinoic acid (RA) signaling promotes differentiation of oligodendrocyte precursor cells (OPCs) and remyelination in a cross talk between neuronal RA receptor-beta (RARβ) and RARα in NG2+cells. We show that stimulation of RARα is required for the differentiation of OPCs and we describe for the first time how oral treatment with a RARβ agonist (C286, currently being tested in a Phase 1 trial,ISRCTN12424734) leads to the endogenous synthesis of RA through retinaldehyde dehydrogenase 2 (Raldh2) in NG2 cells and controls exosome-associated-RA intracellular levels through a decorin–Ca2+pathway. Although RARβ has been implicated in distinct aspects of CNS regeneration, this study identifies a novel function for both RARβ and RARα in remyelination.
- Open Access
- 1 March 2018
- Published by Elsevier in Neurobiology of Disease
- Vol. 111, 70-79
Retinoic acid synthesis by NG2 expressing cells promotes a permissive environment for axonal outgrowth
- 1 March 2018
- Published by Elsevier in Neurobiology of Disease
- Vol. 111, 70-79
Open AccessRetinoic acid synthesis by NG2 expressing cells promotes a permissive environment for axonal outgrowth
- Open Access
- 15 February 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (4) , 798-814
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist
- 15 February 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (4) , 798-814
Open AccessDesign and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist
- Open Access
- 4 February 2013
- Published by Wiley in European Journal of Neuroscience
- Vol. 37 (7) , 1182-1192
Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist
The retinoic acid receptor (RAR) α system plays a key role in the adult brain, participating in the homeostatic control of synaptic plasticity, essential for memory function. Here we show that RARα signalling is down‐regulated by amyloid beta (Aβ), which inhibits the synthesis of the endogenous ligand, retinoic acid (RA). This results in the counteraction of a variety of RARα‐activated pathways that are key in the aetiopathology of Alzheimer's disease (AD) but which can be reversed by an RARα agonist. RARα signalling improves cognition in the Tg2576 mice, it has an anti‐inflammatory effect and promotes Aβ clearance by increasing insulin degrading enzyme and neprilysin activity in both microglia and neurons. In addition, RARα signalling prevents tau phosphorylation. Therefore, stimulation of the RARα signalling pathway using a synthetic agonist, by both clearing Aβ and counteracting some of its toxic effects, offers therapeutic potential for the treatment of AD.
- 4 February 2013
- Published by Wiley in European Journal of Neuroscience
- Vol. 37 (7) , 1182-1192
Open AccessAmyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist
The retinoic acid receptor (RAR) α system plays a key role in the adult brain, participating in the homeostatic control of synaptic plasticity, essential for memory function. Here we show that RARα signalling is down‐regulated by amyloid beta (Aβ), which inhibits the synthesis of the endogenous ligand, retinoic acid (RA). This results in the counteraction of a variety of RARα‐activated pathways that are key in the aetiopathology of Alzheimer's disease (AD) but which can be reversed by an RARα agonist. RARα signalling improves cognition in the Tg2576 mice, it has an anti‐inflammatory effect and promotes Aβ clearance by increasing insulin degrading enzyme and neprilysin activity in both microglia and neurons. In addition, RARα signalling prevents tau phosphorylation. Therefore, stimulation of the RARα signalling pathway using a synthetic agonist, by both clearing Aβ and counteracting some of its toxic effects, offers therapeutic potential for the treatment of AD.